Dr. Reddy's Laboratories has launched Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration (USFDA).
The Syprine brand and generic product had U.S. sales or approximately $94.2 million MAT for the most recent twelve months ending in December 2019 according to IMS Health. The company’s Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles. Syprine is a trademark of Alton Pharma.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharm aceuticals in India and overseas.
